来氟米特(LEF)治疗原发性难治性肾病综合征的疗效及其安全性评价

Efficacy and Safety Evaluation of Leflunomide(LEF) in the Treatment of Primary Refractory Nephrotic Syndrome

目的分析来氟米特治疗原发性难治性肾病综合征的临床效果以及安全性。方法选取2013年1月11日—2016年2月20日来我院就医的原发性难治性肾病综合征患者100例作为本次研究对象。通过动态化随机单双号分组的方法,将其分为两组,分别给予吗替麦考酚酸酯、来氟米特治疗,对比两组患者治疗效果以及不良反应发生情况的差异性。结果观察组患者的完全缓解、显著缓解、部分缓解、无效例数分别为25例、15例、8例、2例;在不良反应发生情况中,肝损伤、恶心呕吐、腹部感染、腹泻的例数分别为1例、1例、1例、0例,与对照组比较,差异具有统计学意义(P<0.05)。结论来氟米特治疗原发性难治性肾病综合征具有一定的应用价值,且不良反应较少,安全有效。

Objective To analyze the clinical efficacy and safety of leflunomide in the treatment of primary refractory nephrotic syndrome. Methods From January 11, 2013 to February 20, 2016 in our hospital, 100 cases of patients with primary nephrotic syndrome were selected as the research objects. The method was divided into two groups by means of dynamic random odd even grouping, which were treated with mycophenolate mofetil and leflunomide. The treatment effect and the difference of adverse reactions between the two groups were compared. Results In the observation group, complete remission, significant remission, partial remission and ineffective cases were 25 cases, 15 cases, 8 cases and 2 cases respectively. In the event of adverse reaction, liver injury, nausea and vomiting, abdominal infection and diarrhea 1 case, 1 case, 1 case, 0 case, compared with the control group, the difference was statistically significant （1~〈0.05）. Conclusion Leflunomide treatment of primary refractory nephrotic syndrome has a certain value, and less adverse reactions, safe and effective.